US Import Tariffs: With 25% Threat, Indian Industry Reads Between Trump Lines

About Half Of Generics Supply From India

US President Trump’s threat of a “25% or higher” import tariff on pharmaceuticals sends ripples through an already uncertain environment. With about half of generics sourced from India, captains of industry read between the lines

Trump's Threat Of US Import Tariffs Looms Large On The Pharma Landscape
Trump's Threat Of US Import Tariffs Looms Large On The Pharma Landscape

The Indian generics and biosimilars manufacturing industry, which accounts for about half of the global generics supply to the US, is concerned about US President Donald Trump’s intention to impose tariffs of “25% or higher” on pharmaceutical, automobile and semiconductor imports.

Multiple media reports have Trump stating that sectoral import tariffs on pharmaceuticals would start at that level, rising substantially over...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from India

Shigella Vaccine Pipeline And Why It Matters

 
• By 

A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease, which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing.

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By 

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Pharma’s Space Trails Entering Transformative Era - Keytruda’s Been There

 

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.

More from Focus On Asia

China Signals Restarting IPOs For Unprofitable Biotechs

 

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By 

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By 

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges